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Abstract 
Background: Tanzania has seen a reduction in the fraction of fevers caused by malaria, likely due in part to scale-up of control 
measures. While national guidelines require parasite-based diagnosis prior to treatment, it is estimated that more than half of 
suspected malaria treatment-seeking in Tanzania initiates in the private retail sector, where diagnosis by malaria rapid diag-
nostic test (RDT) or microscopy is illegal. This pilot study investigated whether the introduction of RDTs into Accredited Drug 
Dispensing Outlets (ADDOs) under realistic market conditions would improve case management practices.
Methods: Dispensers from ADDOs in two intervention districts in Tanzania were trained to stock and perform RDTs 
and monitored quarterly. Each district was assigned a different recommended retail price to evaluate the need for a 
subsidy. Malaria RDT and artemisinin-based combination therapy (ACT) uptake and availability were measured pre-
intervention and 1 year post-intervention through structured surveys of ADDO owners and exiting customers in both 
intervention districts and one contiguous control district. Descriptive analysis and logistic regression were used to 
compare the three districts and identify predictive variables for testing.
Results and discussion: A total of 310 dispensers from 262 ADDOs were trained to stock and perform RDTs. RDT 
availability in intervention ADDOs increased from 1% (n = 172) to 73% (n = 163) during the study; ACT medicines 
were available in 75% of 260 pre-intervention and 68% of 254 post-intervention ADDOs. Pre-treatment testing 
performed within the ADDO increased from 0 to 65% of suspected malaria patients who visited a shop (95% CI 
60.8–69.6%) with no difference between intervention districts. Overall parasite-based diagnosis increased from 19 to 
74% in intervention districts and from 3 to 18% in the control district. Prior knowledge of RDT availability (aOR = 1.9, 
p = 0.03) and RDT experience (aOR = 1.9, p = 0.01) were predictors for testing. Adherence data indicated that 75% of 
malaria positives received ACT, while 3% of negatives received ACT.
Conclusions: Trained and supervised ADDO dispensers in rural Tanzania performed and sold RDTs under real market 
conditions to two-thirds of suspected malaria patients during this one-year pilot. These results support the hypothesis 
that introducing RDTs into regulated private retail sector settings can improve malaria testing and treatment practices 
without an RDT subsidy.
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Background
Malaria prevalence among children under 5  years old 
in Tanzania declined from 18% in 2007 to 9% in 2011, 
whereas 2-week fever prevalence remained approxi-
mately 20% over the same time period, from 19 to 20% [1, 
2]. This reduction in the proportion of fevers caused by 
malaria is likely due at least in part to Tanzania’s recent 
scale-up of prevention and treatment measures [3–5]. 
Presumptive treatment of fevers with artemisinin-based 
combination therapy (ACT) thus will increasingly result 
in incorrect malaria diagnoses, prescription and wastage 
of inappropriate medications, and subsequent delays in 
obtaining effective treatment for the true cause of illness 
[6–9].
The Tanzania National Malaria Control Programme 
(NMCP) case management guidelines require suspected 
malaria cases to receive parasite-based diagnosis by 
microscopy or rapid diagnostic test (RDT) prior to treat-
ment with anti-malarial drugs [10, 11]. In practice, how-
ever, up to 54% of those seeking treatment for suspected 
malaria in Tanzania first visit the private retail sector, 
where malaria diagnostics are currently prohibited from 
being sold and administered [12]. As a result, parasite-
based testing is not received by many suspected malaria 
patients.
The Tanzanian private retail sector includes both 
unregistered outlets and a network of more than 6000 
registered shops or Accredited Drug Dispensing Outlets 
(ADDOs) (duka la dawa muhimu or DLDM in Kiswahili) 
regulated by the Pharmacy Council. Unlike unregistered 
outlets, ADDOs are permitted to stock and sell both 
over-the-counter medicines and certain classes of pre-
scription medications, including ACT [13–15]. To obtain 
a Pharmacy Council permit each year, ADDOs owners 
must meet certain conditions related to the premises, 
training and certification of a dispenser who may or may 
not be the owner, and the products stocked. Like all other 
private retail outlets, RDTs may not be sold or performed 
at ADDOs, however.
Malaria RDTs have been safely administered by non-
medical personnel in several previous settings [16–18]. 
The introduction of RDTs into ADDOs has the potential 
to improve fever case management by increasing avail-
ability, access, and use of parasite-based diagnosis. It is 
unclear, however, whether customers will be willing to 
pay the extra cost for diagnosis, whether ADDO owners 
would encourage RDT use, whether RDTs might require 
subsidization to encourage uptake in the private sec-
tor, and whether treatment choices would adhere to test 
results. To investigate these questions, this pilot evalu-
ated the operational feasibility of selling RDTs through 
ADDOs and measured changes in suspected malaria 
patient case management that occurred as a result of 
making RDTs available at two different prices.
Methods
Study area and population
This pilot was conceived and designed in partnership with 
the NMCP and Pharmacy Council, with a primary objec-
tive of informing national policymaking on legalizing the 
stocking and performance of RDTs through ADDOs. 
The study was conducted in three districts in Morogoro 
Region: Kilombero, Kilosa, and Mvomero. These three dis-
tricts were selected due to their high density of ADDOs, 
moderate Plasmodium falciparum prevalence compared 
with national data (13% in Morogoro Region [2]), and con-
venient proximity to Dar es Salaam. The three districts 
are mostly rural, with a total estimated population of 1.7 
million people in 2012 [19]. Peak malaria incidence corre-
sponds to the two rainy seasons, one between March and 
May and the other between September and December. 
Kilombero and Kilosa were assigned via random number 
generator as the two intervention areas where ADDO dis-
pensers were trained to stock, sell, and administer RDTs, 
and Mvomero served as the control area (Fig. 1).
Intervention design
All licensed ADDO dispensers currently working in an 
ADDO in the two intervention areas were invited to par-
ticipate in the study through the District Malaria Focal 
Person, who is responsible for overseeing local malaria-
related activities under the leadership of the District 
Medical Officer. In April–May 2013, six two-day train-
ings were held in each intervention district, each led by 
a national-level trainer and the district malaria focal per-
son. Trainings covered signs and symptoms of uncompli-
cated and severe malaria, stocking, use, and disposal of 
RDTs, and appropriate case management based on RDT 
results. Dispensers were instructed to prescribe Tan-
zania’s first-line treatment, artemether  +  lumefantrine 
(commonly referred to as ALu in Tanzania), to test-pos-
itive customers based on an ALu dosing reference chart 
provided to the dispensers. Dispensers were trained to 
refer customers with signs and symptoms of severe ill-
ness, suspected malaria patients who tested negative for 
malaria, and suspected malaria patients whose illness 
did not improve within 48 h to the nearest public health 
facility along with the results of their malaria test.
Keywords: Parasite-based malaria diagnosis, Rapid diagnostic test, Private retail sector, Tanzania
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Upon passing both practical and written evaluations, 
certified RDT dispensers were provided with an ID badge 
granting permission to perform RDTs in their ADDO, a 
sharps box, an RDT performance and case management 
job aid, and a weather-proof storefront sign advertising 
that malaria testing was available. Permission was also 
granted for the ADDO dispenser to prescribe an ALu to 
all patients who tested positive for malaria.
To mimic real market conditions, existing supply 
chains were utilized: ADDOs in the two districts were 
instructed to purchase ParaHIT® Ag Pf RDTs from seven 
wholesalers. The wholesalers, in turn, were instructed to 
purchase RDTs from an importer in Dar es Salaam, who 
purchased the RDTs directly from the manufacturer for a 
fixed price pre-negotiated by the research team. Import-
ers, wholesalers and ADDOs all agreed to fixed mark ups.
ADDOs in Kilosa were asked to sell RDTs for a recom-
mended retail price (RRP) of 1100 Tanzanian Shillings 
(USD $0.67 in May 2013) each, based on willingness-
to-pay responses from pre-intervention exit interviews, 
analysis of markups in analogous commodities, and price 
negotiation. In Kilombero, ADDOs were asked to sell 
RDTs for 50% less or 500 Tanzanian Shillings (USD $0.32 
in May 2013) [20]. To enable the ADDOs in Kilombero 
to charge the lower price, the research team asked the 
importer to sell RDTs to wholesalers in Kilombero at a 
50% discount. On a monthly basis, the importer received 
financial compensation from the research team equal to 
the total discount provided to wholesalers located in Kil-
ombero. The research team monitored stock levels at the 
importer level to prevent stock outs.
Gloves were included in the RDT boxes. A unique blue-
and-white “mRDT” checkmark logo was placed on Para-
HIT® boxes, ID badges, job aids, and storefront signs in 
order to build brand recognition.
Trained study staff provided supportive supervi-
sion during quarterly monitoring visits. At each visit, 
the certified dispenser at each participating ADDO was 
observed performing an RDT on a patient and evaluated 
according to a 17-point checklist adapted from the WHO 
“Checklist for direct observation of health workers per-
forming Rapid Diagnostic Tests (RDT) for malaria” [21]. 
The supervisors also reported on stocking safety, shop 








T A N Z A N I A
Fig. 1 Map of the study area
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Study design
The impact of the intervention was assessed by compar-
ing the change in availability and use of RDTs at ADDOs 
in the intervention districts with those in the control dis-
trict, Mvomero, where ADDOs were not given access to 
the RDTs, training, or supervision.
Outlet surveys
RDT and ACT availability were measured through two 
cross-sectional ADDO surveys, one conducted prior to 
the dispenser training in March 2013 and the second a 
year after the 2013 training, in May 2014. All ADDOs 
were eligible for selection for the pre-intervention survey, 
while only ADDOs with certified dispensers were eligi-
ble to participate in the post-intervention survey of the 
intervention districts. Ninety-one ADDOs per district 
were selected using random number generation based on 
sample-size calculations to ensure 80% power. The sam-
ple size is assumed to be sufficient to detect a five per-
centage-point difference in ADDO RDT availability.
A Kiswahili or English-version structured question-
naire was used during the face-to-face interviews with 
ADDO dispensers depending on the language preference 
of the respondent. The primary outcome was RDT avail-
ability, defined as the proportion of ADDOs with RDTs in 
stock on the day of the survey and a trained, certified dis-
penser present to administer the test. A secondary out-
come was ACT availability, defined as the proportion of 
ADDOs that reported having ACT medicines in stock for 
the 30 days prior to the survey.
Customer exit interviews
Face-to-face exit interviews were conducted prior to 
the dispenser training (March 2013) and a year after the 
intervention began (May 2014) using a structured ques-
tionnaire in Kiswahili. Customers eligible for the exit 
interview were at least 18  years old and either seeking 
treatment in the ADDO for fever or suspected malaria 
or attempting to purchase an anti-malarial for them-
selves or someone else (the “patient”). A sample size of 
400 eligible customers per district was estimated based 
on two-tailed sample size calculations designed to detect 
a 5%-point difference in RDT availability or 80% power. 
Pre-intervention, 1–3 customers were interviewed at 
each sampled ADDO. The sample size was halved for 
the pre-intervention survey based on very low predicted 
availability of RDTs and a primary goal of comparing 
similarity between districts. Post-intervention, enumera-
tors attempted to survey all eligible customers during one 
full day at the ADDO in order to self-weight traffic varia-
tion between shops.
If the customer and the patient were not the same 
person, demographic data were collected on both the 
customer and the patient, and illness data were col-
lected about the patient. Customers were asked whether 
patients (either themselves or others) had received diag-
nostic testing at the ADDO, had been previously tested 
elsewhere, how much they had paid for RDTs at the 
ADDO, and whether they had purchased anti-malarial 
treatment.
Statistical analysis
Chi square tests were used to compare differences before 
and after intervention and between intervention and 
control districts in (a) the proportion of patients seek-
ing treatment at ADDOs who received a parasite-based 
diagnostic test, (b) the median price paid for an RDT in 
an ADDO, (c) the proportion of patients who received 
a parasite-based diagnosis, (d) adherence to test results 
in terms of receiving ACT when testing positive and not 
receiving one when testing negative, and (e) the propor-
tion of test-negative patients who received an antibiotic.
Logistic regression models were then used to identify 
factors associated with receiving an RDT in an ADDO 
or receiving a parasite-based diagnosis anywhere, with 
shop included as a random effect to account for repeated 
sampling of visits to the same ADDOs. Tested covariates 
included study district and survey, demographic variables 
(customer and patient gender, age, completed education, 
and wealth quintile) as well as RDT knowledge and prac-
tice indicators regarding previous experience and atti-
tudes about testing. Wealth quintiles were derived from 
a wealth index based on a set of household asset ques-
tions estimated using principal components analysis 
using similar methodology to Demographic and Health 
Surveys [23]. Covariates with p < 0.2 in bivariable models 
were included in multivariable models. Logistic regres-
sion models were also used to compare odds of treatment 
outcomes controlling for study district, survey, parasite-
based diagnosis, and test result.
Results
Ninety-five percent of ADDO dispensers passed the 
2-day training. In total, 310 dispensers from 262 ADDOs, 
164 (147 ADDOs) from Kilombero in the lower-priced or 
“subsidized” district and 146 (115 ADDOs) from Kilosa 
the higher priced or “unsubsidized” district, were certi-
fied and allowed to sell and perform RDTs. The number 
of outlet surveys and exit interviews completed are pre-
sented in Table 1.
Diagnostic and treatment availability in ADDOs
Pre-intervention outlet surveys found that RDTs were not 
available in any surveyed ADDOs. Post-intervention, 73% 
of ADDOs in intervention districts had RDTs in stock 
and an RDT-certified dispenser present. The proportion 
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of ADDOs with a certified dispenser and RDTs available 
was higher in the “unsubsidized” district Kilosa (85%, 
95% CI 78–92%) than the “subsidized” district Kilombero 
(64%, 95% CI 55–72%, p < 0.001). Across the study dis-
tricts, the proportion of ADDOs with ACTs available was 
75% pre-intervention and 68% post-intervention. ACT 
availability did not differ significantly between districts or 
pre- or post-intervention (p > 0.05 for all).
Customer and patient characteristics
A total of 1214 customers seeking treatment for sus-
pected malaria, either for themselves or someone else, 
were interviewed: 259 pre-intervention and 955 post-
intervention (Table  1). Demographic characteristics of 
customers were generally similar between districts dur-
ing each survey (Table  2). The proportion of exit inter-
views in which the patient was present at the ADDO 
was significantly higher in intervention districts post-
intervention. ADDOs were the first place treatment was 
sought for 75% of patient visits across surveys and dis-
tricts (Table 3).
Diagnostic uptake
Pre-intervention, no patients present in the ADDOs 
reported receiving a parasite-based test in an ADDO in 
any district. Post-intervention, 65% of patients present at 
ADDOs in the intervention districts (95% CI 60.8–69.6%) 
and 3% in the control district received an RDT (Fig. 2a). 
There was no difference in the fraction of eligible patients 
who were tested between the subsidized (66%, 95% 
CI 59–72%) and unsubsidized districts (67%, 95% CI 
58–71%), (χ2 < 0.1, p = 0.8).
Overall diagnostic uptake (in ADDOs or elsewhere 
prior to the ADDO visit) improved significantly in 
the intervention and control groups during the study 
(Fig.  2b). The proportion of patients present at the 
ADDO who received a diagnostic test increased from 
19% pre-intervention to 74% post-intervention in the 
intervention districts and from 3 to 18% in the control 
district (p < 0.01 for both groups). The relative changes in 
testing were not significantly different between the inter-
vention and control districts (OR = 2.5, p = 0.271).
Median prices for RDTs post-intervention reported 
by customers were 1100 Tanzanian Shillings in Kilosa, 
the unsubsidized district, and 500 Tanzanian Shillings 
in Kilombero, the subsidized district. There was no 
variance in median price from the recommended retail 
price in either district. No difference in RDT uptake was 
observed between the unsubsidized and subsidized dis-
tricts (OR = 1.1, p = 0.868).
Patient knowledge and practices were associated with 
RDT purchasing (Table  4). The odds of purchasing an 
RDT were significantly higher for patients who had previ-
ous experience taking an RDT or were already aware that 
RDTs were available before coming to the ADDO, while 
patients who had sought treatment elsewhere before vis-
iting the ADDO were significantly less likely to purchase 
an RDT.
Treatment decisions
The overall proportion of patients who received an ACT 
increased from 40 to 43% in the control district and 
decreased from 40 to 32% in the intervention districts, 
although these changes were not significantly different 
after controlling for other factors (OR = 0.6, p = 0.294). 
Forty-one percent of patients who received an RDT tested 
positive for malaria across the intervention districts (95% 
CI 35.7–46.8%). Among patients with a positive test, 90% 
(95% CI 81.9–94.9%) received an anti-malarial, and 75% 
(95% CI 65.5–83.5%) received ACT. Among customers 
Table 1 Total shop and exit interviews conducted and included in analysis
a ’ACT in stock’ defined as no stock-outs in the past 30 days
b Only customer interviews from shops with ACT medicines in stock and the patient present were included in analysis (i.e., the patient had the opportunity to be 
tested and purchase an ACT medicine)



























87 59 91 54 76 52 266 217
Unsubsidized 
(Kilosa)
85 66 82 46 87 63 330 247
Control 
(Mvomero)
88 69 86 59 91 57 359 244
Total 260 194 259 159 254 172 955 708
Page 6 of 10Maloney et al. Malar J  (2017) 16:6 
testing negative, 7% (95% CI 3.6–12.3%) received an anti-
malarial (Fig. 3a). There was no significant difference in 
the proportion of those who did not receive an RDT who 
purchased an anti-malarial (35% in intervention districts, 
41% in control) (Fig. 3b).
The proportion of patients who received an antibiotic 
did not change significantly comparing intervention and 
control groups from pre- to post-intervention (OR = 0.9, 
p = 0.837). Post-intervention, the proportion of patients 
purchasing antibiotics also did not vary significantly 
comparing those who tested positive with those who 
tested negative (10% vs 9%, p = 0.73) (Fig. 3a).
Discussion
The results from this study suggest that ADDOs offer an 
important opportunity for improving malaria case man-
agement in Tanzania towards the national goal of 80% 
parasite-based diagnosis of suspected malaria patients. 
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 Lower 20.9 (12.4–29.3) 18.3 (9.8–26.8) 20.9 (12.2–29.6) 21.8 (16.8–26.8) 21.9 (17.4–26.4) 18.1 (14.1–22.1)
 Middle 23.1 (14.3–31.8) 13.4 (6.0–20.9) 22.1 (13.2–31.0) 22.9 (17.9–28.0) 18.2 (14.1–22.4) 20.6 (16.4–24.8)
 Higher 20.9 (12.4–29.3)  20.7 (11.9–29.6) 20.9 (12.2–29.6) 20.3 (15.5–25.1) 21.3 (16.8–25.7) 17.5 (13.6–21.5)
 Highest 20.9 (12.4–29.3) 17.1 (8.8–25.3) 18.6 (10.3–26.9) 17.3 (12.7–21.9) 20.4 (16.0–24.7) 18.9 (14.9–23.0)
Patient is 





59.3 (49.1–69.5) 59.1 (45.2–67.0) 68.6 (58.7–78.5) 0.221 81.6 (76.9–86.3) 74.8 (70.2–79.5) 68.0 (63.1–72.8) 0.001


















24.5 (1–66) 22 (<1–62) 27 (<1–83) 23 (<1–79) 22 (1–92) 24 (1–74)
Male (%, 95% CI) 48.1 (34.6–61.7) 47.8 (33.1–62.5) 50.8 (37.8–63.8) 0.941 47.9 (41.2–54.6) 53.0 (46.8–59.3) 50.8 (44.5–57.1) 0.546
Days Ill (median, 
range)
3 (<1, 14) 3 (<1, 30) 3 (<1, 14) 2 (<1, 60) 3 (<1, 30) 2 (<1, 60)




70.4 (58.0–82.8) 65.2 (51.2–79.2) 80.0 (69.2–90.1) 0.240 77.4 (71.8–83.0) 74.8 (69.4–80.2) 75.4 (70.0–80.8) 0.792
Malaria test 
prior to ADDO 
Visit (%, 95% 
CI)
16.7 (6.6–26.8) 21.7 (9.6–33.9) 3.4 (0.0–8.1) 0.015 11.1 (6.8–15.4) 13.4 (9.0–17.8) 14.9 (10.2–19.7) 0.502
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Two-thirds of suspected malaria patients who sought 
treatment at ADDOs with RDT-certified dispensers pur-
chased RDTs. Improved testing rates through ADDOs in 
this pilot project resulted in improved targeting of ACTs 
to patients with malaria, with 90% of malaria-positive 
and 93% of malaria-negative ADDO-tested patients mak-
ing appropriate treatment decisions according to their 
test results.
These results add to a growing body of evidence that 
malaria case management can be performed well outside 
of the formal public health sector. A pilot in Ghana that 
measured vendor-reported adherence to test results after 
the introduction of RDTs to 28 Licensed Chemical Sell-
ers (private retail sector shops) found 89% of positives 
and 3% of negatives received ACT [24]. Vendors of 59 
licensed drug shops in Uganda also reported high uptake 
(98%) and favorable adherence to test results (ALu was 
prescribed to 98% of positives and 1% of negatives) in a 
small-scale pilot study [25]. The higher uptake observed 
in these studies compared with this one may be attributa-
ble to self-reporting by drug shop vendors compared with 
customer interviews, a lower $0.20 price point (Uganda) 
compared to $0.31–0.67 in Tanzania, and/or variance in 
length of training and frequency of supervision. Not all 
studies have found such positive outcomes, however: a 
different study in Uganda with 92 shops selling RDTs that 
measured adherence through household surveys found 
only 32% of positives purchased an ACT medicine (7% of 
negatives) at a median $0.40 per test [16].
This pilot was successful in improving case manage-
ment practices for several reasons. First, ADDOs are 
a highly utilized source for anti-malarials in Tanzania: 
ADDOs were the first place treatment was sought for 75% 
of interviewed patients, emphasizing the need for access 
to parasite-based diagnosis at this point of care. Second, 
nearly all ADDOs in the study area participated in the 
trainings and RDT program. ADDOs were kept engaged 
in the study through quarterly supervision and monitor-
ing visits, which also allowed for frequent quality assess-
ments on safety protocol. Third, proximity of the region 
to Dar es Salaam and relatively good road infrastructure 
allowed for existing supply chains to be utilized, creat-
ing a more realistic market scenario. Finally, negotiations 
with RDT suppliers and agreements with wholesalers and 
ADDOs on mark ups, ensured affordable recommended 
retail prices and enabled comparison of price points.
These results provided data to help guide several open 
questions surrounding an introduction of RDTs to the 
private retail market. A similar proportion of patients 
were willing to pay the higher ‘unsubsidized’ price of a 
1100 Tanzanian Shillings or USD $0.67 for a RDT com-
pared to the lower unsubsidized price of 500 Tanzania 
Shillings or USD $0.32 for the subsidized RDT, indicating 
that a subsidy may not be necessary to encourage test-
ing uptake. Additionally, similar to the Ghana pilot [24], 
an increase in the purchase of antibiotics among those 
receiving a negative test result was not observed in this 
study.
The study was also subject to several limitations. A 
significant pre-intervention difference in parasite-based 
diagnostic rates between intervention (19%) and con-
trol (3%) districts suggests inherent differences in health 
facility testing uptake that may confound the effect of 
the intervention. A second limitation was the unforeseen 
mobility of ADDO dispensers, periodically changing jobs 





























































Fig. 2 a Proportion of patients present at the ADDO who received a parasite-based diagnosis before and after intervention (p < 0.001 for changes 
in intervention districts; p = 0.159 for the control district). b Proportion of patients present in the ADDO reporting receiving parasite-based diagnos-
tics at any location (p < 0.05 for pre- to post-intervention changes within each district)
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dispensers were certified in this study, it was unclear if 
the certification extended to the ADDO when the dis-
penser was not present. Dispenser movement compli-
cated follow-up and suggests future consideration for 
specifying that dispensers and ADDOs be certified, and 
requiring ADDOs that sell RDTs to have a certified dis-
penser present. Additional follow-up challenges arose 
when ADDOs closed temporarily or permanently, or 
were not reachable for stock delivery or enumeration due 
to flooded roads and bridges. Also, although dispens-
ers were trained to refer severe and negative cases to 
the nearest health facility, this study was not resourced 
to follow the outcomes of these patients. In practice, it 
is unlikely that all negative cases will complete the refer-
ral pathway, underscoring the importance of including 
diagnosis and treatment of non-malaria febrile illness 
and recognition of danger signs in ADDO dispenser 
training. Lastly, the post-intervention survey sampled 
from ADDOs that participated in the training in the 
intervention areas, and while these were the majority of 
the ADDOs in these districts, they are not representative 
of all ADDOs in the study area.
As Tanzania uses the results of this study to inform 
policy decisions, it will be important to consider how 
results might vary in different endemic settings and in 
more urban areas. Expansion of this program will also 
require evaluation of how best to ensure long-term rou-
tine supervision and training, as well as waste manage-
ment for sharps and cassettes. Finally, a critical challenge 
to scale-up will be integration of the private retail sector 
Table 4 Factors associated with purchasing an RDT in the ADDO when the patient was present
Outcome: receiving an RDT in an ADDO if present to be tested (n = 464) Bivariable Multivariable
OR 95% CI p value OR 95% CI p value
Intervention
 No subsidy Reference
 Subsidy 1.1 (0.6–1.9) 0.868
Customer gender (if not patient)
 Female Reference
 Male 1.2 (0.5–2.7) 0.654
Patient gender
 Female Reference
 Male 1.0 (0.7–1.4) 0.920
Customer age (if not patient) 1.0 (1.0–1.0) 0.198
Patient age
 <5 years Reference
 5− <14 years 1.5 (0.7–3.5) 0.332
 14+ years 0.7 (0.3–1.3) 0.254
Customer education
 Primary Reference
 Secondary and above 1.0 (0.6–1.6) 0.909
Wealth index
 Lowest Reference
 Lower 1.0 (0.5–2.0) 0.925
 Middle 0.9 (0.4–1.8) 0.723
 Higher 1.2 (0.6–2.5) 0.559
 Highest 1.0 (0.5–2.2) 0.943
Has heard of RDTs 3.1 (2.0–4.8) <0.001 1.7 (0.9–3.1) 0.088
Has taken an RDT before 3.1 (2.1–4.7) <0.001 1.9 (1.2–3.0) 0.005
Sought treatment prior to ADDO visit 0.3 (0.2–0.5) <0.001 0.3 (0.2–0.5) <0.001
Knew before coming that testing was available in ADDOs 3.0 (2.0–4.7) <0.001 1.9 (1.1–3.3) 0.032
Believes febrile patients should be blood tested before treating
 Never Reference
 Sometimes 1.1 (0.1–8.9) 0.925
 Always 2.0 (0.3–13.9) 0.474
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into the routine surveillance system for capturing malaria 
case data. This information will be imperative for stra-
tegic decision-making as malaria prevalence declines 
across the country.
Conclusions
This pilot study contributes to a growing evidence base 
that introducing RDTs to the private retail sector in low 
resource settings can increase parasite-based diagnostic 
rates for malaria and adherence to test results when dis-
pensers are trained and supervised. The pilot study also 
showed that RDTs can be introduced under real mar-
ket conditions; utilizing existing supply chains without 
subsidizing the cost of the RDT. While the intervention 
piloted here was limited to a rural setting in Tanzania’s 
specialized ADDO network, it provides a basis for pol-
icy decisions on scaling up RDT access across Tanzania 
to increase parasite-based diagnosis and rational use of 
ACT through heavily used existing channels. The results 
presented here support the goals for Tanzania’s National 
Strategic Plan and may have applications in similar 
settings.
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